

# EXHIBIT D



## LETTER OF RELIANCE


Mail Stop **Hatch-Waxman PTE**  
Office of Patent Legal Administration  
Room MDW 7D55  
600 Dulany Street (Madison Building)  
Alexandria, VA 22314

Attn: Mary C. Till, Examiner  
Office of Patent Legal Administration

**Gilead Sciences, Inc.**, Licensee of the exclusive rights to U.S. Patent No. 5,840,722 ("U.S. '722"), authorizes **Abbott Laboratories**, Licensor and record-owner of U.S. '722, to rely on the activities of Gilead Sciences, Inc. supporting FDA approval of LETAIRIS™ (ambrisentan) product (5 and 10 mg tablets), for the purpose of obtaining extension of patent term of U.S. '722, as provided under 35 U.S.C. §156(d)(1), 37 C.F.R. §1.730 and MPEP 2752.

Date: 8/2/07

Authorized by Gilead Sciences, Inc.

By:   
Richard J. Gorczynski, PhD  
SVP, Cardiovascular Therapeutics